Performance of serum soluble interleukin-2 receptor as a diagnostic marker for lymphoma in patients with fever.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
10
12
2022
accepted:
04
10
2023
medline:
3
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
epublish
Résumé
There have been few reports on the diagnostic performance of soluble interleukin-2 receptor (sIL-2R) for lymphoma. A cross-sectional study was conducted at a university hospital; all patients who were admitted to the Division of General Internal Medicine and underwent serum sIL-2R testing were included. Patients were divided into two groups based on the presence of fever (≥ 38.0 °C). Among 602 patients, 421 had fever and 76 were diagnosed with lymphoma (48 of the 76 were in the febrile group). In all patients, the area under the receiver operating characteristic curve (AUROC) of sIL-2R for the diagnosis of lymphoma was 0.81 [95% confidence interval (CI), 0.75-0.87]. The AUROC was significantly higher in the febrile group (0.88; 95% CI, 0.81-0.94) than in the afebrile group (0.75; 95% CI, 0.65-0.85). In the febrile group, the sensitivity and specificity were 81.2% and 82.3%, respectively, with an optimal cutoff value of 3,250 U/mL. In the afebrile group, they were 89.3% and 54.9%, respectively, with a cutoff value of 868 U/mL. Serum sIL-2R showed high performance as an adjunctive diagnostic marker for lymphoma, particularly among febrile patients. Different cutoff values should be used for patients with and without fever to maximize diagnostic performance.
Identifiants
pubmed: 37914769
doi: 10.1038/s41598-023-44123-5
pii: 10.1038/s41598-023-44123-5
pmc: PMC10620379
doi:
Substances chimiques
Receptors, Interleukin-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18784Informations de copyright
© 2023. The Author(s).
Références
Ann Hematol. 2017 Aug;96(8):1241-1251
pubmed: 28497365
Clin Exp Immunol. 2006 Nov;146(2):243-52
pubmed: 17034576
Blood. 1991 Nov 15;78(10):2626-32
pubmed: 1726707
Cytokine. 2004 Nov 7;28(3):109-23
pubmed: 15473953
Int J Clin Oncol. 2019 Sep;24(9):1151-1160
pubmed: 31183777
Blood Adv. 2017 Dec 06;1(26):2529-2534
pubmed: 29296904
Ren Fail. 2020 Nov;42(1):419-427
pubmed: 32401100
Leuk Lymphoma. 2014 Jul;55(7):1584-90
pubmed: 24180329
J Educ Health Promot. 2020 Feb 28;9:48
pubmed: 32318616
Respir Med. 2015 Feb;109(2):279-85
pubmed: 25496652
Ann Hematol. 2012 May;91(5):705-714
pubmed: 22183251
Dermatology. 2012;224(1):46-50
pubmed: 22414723
Intern Med. 2012;51(18):2529-36
pubmed: 22989822
Neth J Med. 2020 Sep;78(5):220-231
pubmed: 33093245
Anticancer Res. 2021 Feb;41(2):1021-1026
pubmed: 33517310
J Infect Dis. 1997 Jan;175(1):142-5
pubmed: 8985208
Hematology. 2017 Oct;22(9):521-526
pubmed: 28413914
Psychoneuroendocrinology. 2009 Jan;34(1):118-28
pubmed: 18835660
Mol Clin Oncol. 2019 Nov;11(5):474-482
pubmed: 31620278
Ann Oncol. 2009 Mar;20(3):526-33
pubmed: 19074749
Br J Haematol. 1990 Feb;74(2):233-4
pubmed: 2317461